What is Stifel Canada’s Forecast for TSE:CPH Q1 Earnings?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Equities researchers at Stifel Canada issued their Q1 2025 earnings per share estimates for Cipher Pharmaceuticals in a report released on Monday, March 24th. Stifel Canada analyst J. Keywood anticipates that the company will earn $0.21 per share for the quarter. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ Q2 2025 earnings at $0.24 EPS, Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.26 EPS and FY2025 earnings at $0.99 EPS.

Cipher Pharmaceuticals Price Performance

Shares of Cipher Pharmaceuticals stock opened at C$12.32 on Wednesday. Cipher Pharmaceuticals has a 1-year low of C$7.90 and a 1-year high of C$19.69. The firm has a fifty day simple moving average of C$12.85 and a 200-day simple moving average of C$14.38. The company has a current ratio of 2.00, a quick ratio of 2.67 and a debt-to-equity ratio of 41.22. The stock has a market capitalization of C$221.18 million, a price-to-earnings ratio of 13.61 and a beta of 1.20.

Insiders Place Their Bets

In other news, Director Harold Morton Wolkin sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of C$13.49, for a total transaction of C$47,215.00. Company insiders own 42.00% of the company’s stock.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.